Long-term protective efficacy of recombinant CHO cell-derived hepatitis B vaccine：A 26-year follow-up study in Zhengding county
10.3760/cma.j.cn112866-20250226-00044
- VernacularTitle:重组CHO乙型肝炎疫苗长期免疫效果评价：正定县监测点26年跟踪研究
- Author:
Qiudong SU
1
;
Zhiyong HAO
;
Feng QIU
;
Lili QIAO
;
Huijuan JIA
;
Shuang ZHANG
;
Pengpeng YUAN
;
Juan CHU
;
Zhiyong ZHANG
;
Junfang YAO
;
Jinling WEI
;
Yan WANG
;
Peiqi ZHAO
;
Yujiao LIU
;
Zhao GAO
;
Jingchen MA
;
Feng WANG
;
Haisong ZHOU
Author Information
1. 中国疾病预防控制中心病毒病预防控制所 国家卫生健康委医学病毒和病毒病重点实验室，北京 102206
- Publication Type:Journal Article
- Keywords:
Hepatitis B vaccine;
Antibody;
Immunological persistence;
Long-term protective efficacy
- From:
Chinese Journal of Experimental and Clinical Virology
2025;39(4):434-440
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the long-term protective efficacy of the recombinant Chinese hamster ovary cell-derived hepatitis B vaccine（CHO-HepB）26 years post-vaccination in the rural China.Methods:Zhengding county，Hebei province was designated as a rural monitoring site for CHO-HepB efficacy. Study participants included individuals born between 1997 and 1999 who had completed the three-dose CHO-HepB primary series without booster doses. A cross-sectional survey was conducted in late 2024 using random sampling. Demographic and vaccination history data were collected via questionnaires，and hepatitis B virus（HBV）serological markers were detected using chemiluminescence. Historical surveillance data were integrated to infer infection statuses of HBsAg-positive individuals and evaluate longitudinal trends in anti-HBs seropositivity and antibody titers.Results:Among 178 participants（mean time since vaccination：26.2 years），the seroprevalence rates were 0.6% for HBsAg（95% CI：0.0%-1.6%），64.6% for anti-HBs（95% CI：57.6%-71.6%），and 1.1% for anti-HBc（95% CI：0.0%-2.7%）. Compared to the pre-vaccination baseline HBsAg positivity of 11.3% in children under 10 years of age，the estimated vaccine protection rate was 95%. Two notable cases were identified：one with concurrent HBsAg and anti-HBc positivity and one with anti-HBs and anti-HBc positivity，suggestive of transient HBV exposure（1999—2009）without chronicity. Natural immune boosting was inferred for the latter case based on anti-HBs titer dynamics. Longitudinal analysis of four prior cross-sectional surveys（2005，2009，2013，and 2017）revealed no significant upward trends in HBsAg and anti-HBc positivity（both P>0.05）over 26 years，while anti-HBs seropositivity declined significantly（ P<0.05）from 6 to 26 years post-vaccination. Conclusion:The CHO-HepB vaccine demonstrates sustained immunological persistence and robust long-term protection up to 26 years post-immunization. Continued emphasis on rigorous implementation of mother-to-child transmission prevention strategies is critical for future hepatitis B control.
